Cellular consequences of oxidative stress in riboflavin responsive multiple acyl-CoA dehydrogenation deficiency patient fibroblasts.
Mitochondrial dysfunction and oxidative stress are central to the molecular pathology of many human diseases. Riboflavin responsive multiple acyl-CoA dehydrogenation deficiency (RR-MADD) is in most cases caused by variations in the gene coding for electron transfer flavoprotein-ubiquinone oxidoreductase (ETF-QO). Currently, patients with RR-MADD are treated with high doses of riboflavin resulting in improvements of the clinical and biochemical profiles. However, in our recent studies of RR-MADD, we have shown that riboflavin treatment cannot fully correct the molecular defect in patient cells producing increased reactive oxygen species (ROS). In the current study, we aim to elucidate the cellular consequences of increased ROS by studying the cellular ROS adaption systems including antioxidant system, mitochondrial dynamics and metabolic reprogramming. We have included fibroblasts from six unrelated RR-MADD patients and two control fibroblasts cultivated under supplemented and depleted riboflavin conditions and with coenzyme Q10 (CoQ10) treatment. We demonstrated inhibition of mitochondrial fusion with increased fractionation and mitophagy in the patient fibroblasts. Furthermore, we indicated a shift in the energy metabolism by decreased protein levels of SIRT3 and decreased expression of fatty acid β-oxidation enzymes in the patient fibroblasts. Finally, we showed that CoQ10 treatment has a positive effect on the mitochondrial dynamic in the patient fibroblasts, indicated by increased mitochondrial fusion marker and reduced mitophagy. In conclusion, our results indicate that RR-MADD patient fibroblasts suffer from a general mitochondria dysfunction, probably initiated as a rescue mechanism for the patient cells to escape apoptosis as a result of the oxidative stress.
Research Unit for Molecular Medicine, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Brendstrupgaardsvej 100, Aarhus 8200, Denmark and nanna.cornelius@ki.au.dk rikke.olsen@ki.au.dk.
Nanna
N
Cornelius
Department of Biomedicine, Aarhus University, Aarhus 8000, Denmark.
Thomas J
TJ
Corydon
Research Unit for Molecular Medicine, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Brendstrupgaardsvej 100, Aarhus 8200, Denmark and.
Niels
N
Gregersen
Research Unit for Molecular Medicine, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University, Brendstrupgaardsvej 100, Aarhus 8200, Denmark and nanna.cornelius@ki.au.dk rikke.olsen@ki.au.dk.
Rikke K J
RK
Olsen
D000975:Antioxidants / Q000378:metabolism; D002478:Cells, Cultured; D065150:Cellular Reprogramming / Q000187:drug effects; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D008928:Mitochondria / Q000378:metabolism; D063154:Mitochondrial Dynamics / Q000187:drug effects; D054069:Multiple Acyl Coenzyme A Dehydrogenase Deficiency / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects*; D012256:Riboflavin / Q000494:pharmacology*; D012867:Skin / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000494:pharmacology; D014815:Vitamins / Q000494:pharmacology*
D000975:Antioxidants; D014815:Vitamins; D014451:Ubiquinone; C024989:coenzyme Q10; D012256:Riboflavin